Oct. 4, 2024
- The 5th SMC meeting held today to discuss the clinical data of the 3 subjects at the dose level of 1.0 mg/kg, Schedule B (twice/week). All the voting members of the SMC voted to advance to the next dose level at 2.0 mg/kg, Schedule B (twice/week) due to no DLT observed during DLT observation period at 1.0 mg/kg, Schedule B (twice/week).